Top

Published in:

01-05-2018 | Original Article

Effects of atorvastatin on myocardial oxidative and nitrosative stress in diabetic rats

Authors: Habib Yaribeygi, Nastaran Faghihi, Mohammad Taghi Mohammadi, Amirhossein Sahebkar

Published in: Comparative Clinical Pathology | Issue 3/2018

Abstract

Free radicals play a pivotal role in many pathophysiological states, such as myopathies. Atorvastatin is a known cholesterol-lowering agent with many pleiotropic actions including antioxidant properties. However, the impact of atorvastatin on myocardial oxidative stress is not well known. The aim of this study was to evaluate the role of atorvastatin in improving diabetes-induced oxidative stress in the myocardium. Male Wistar rats weighing 20–25 g were randomly divided into four groups as normal, normal-treated, diabetes, and diabetes-treated. Induction of diabetes was performed by a single dose of streptozotocin (40 mg/kg, i.v.). Treated animals received atorvastatin for 8 weeks orally (40 mg/kg/day). After 8 weeks, animals were sacrificed and myocardial tissues were removed. Then, nitrate, glutathione (GSH), and malondialdehyde (MDA) contents as well as enzymatic activities of catalase (CAT) and superoxide dismutase (SOD) in the myocardial tissues were determined. Diabetes-induced oxidative stress by increasing nitrous free radicals (nitrate) (p ≤ 0.001) and MDA content (p ≤ 0.001), but had no significant effects on SOD, CAT, and GSH activities. Atorvastatin treatment in diabetic animals decreased free radical-induced damages by decreasing nitrate and MDA content and increasing GSH and SOD activities compared to control non-diabetic animals. Uncontrolled hyperglycemia induces oxidative burden in myocardium. Treatment by atorvastatin decreases oxidative and nitrosative stress in the myocardium of diabetic animals.

Aebi H (1984) [13] Catalase in vitro. Methods Enzymol 105:121–126. https://doi.org/10.1016/S0076-6879(84)05016-3 CrossRefPubMed

Belch J, Bridges A, Scott N, Chopra M (1991) Oxygen free radicals and congestive heart failure. Br Heart J 65(5):245–248. https://doi.org/10.1136/hrt.65.5.245 CrossRefPubMedPubMedCentral

Chruściel P, Sahebkar A, Rembek-Wieliczko M, Serban MC, Ursoniu S, Mikhailidis DP, Jones SR, Mosteoru S, Blaha MJ, Martin SS, Rysz J, Toth PP, Lip GY, Pencina MJ, Ray KK, Banach M, Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (2016) Impact of statin therapy on plasma adiponectin concentrations: a systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis 253:194–208. https://doi.org/10.1016/j.atherosclerosis.2016.07.897 CrossRefPubMed

Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, Nicotera T (1996) Oxidative damage to DNA in diabetes mellitus. Lancet 347(8999):444–445. https://doi.org/10.1016/S0140-6736(96)90013-6 CrossRefPubMed

Dhalla NS, Temsah RM, Netticadan T (2000) Role of oxidative stress in cardiovascular diseases. J Hypertens 18(6):655–673. https://doi.org/10.1097/00004872-200018060-00002 CrossRefPubMed

Ferretti G, Bacchetti T, Sahebkar A (2015) Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials. Prog Lipid Res 60:50–73. https://doi.org/10.1016/j.plipres.2015.08.003 CrossRefPubMed

Forbes JM, Cooper ME (2013) Mechanisms of diabetic complications. Physiol Rev 93(1):137–188. https://doi.org/10.1152/physrev.00045.2011 CrossRefPubMed

Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD (2011) Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 106(1):71–77. https://doi.org/10.1038/ajg.2010.299 CrossRefPubMed

Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, Nadal-Ginard B, Anversa P (2000) Myocardial cell death in human diabetes. Circ Res 87(12):1123–1132. https://doi.org/10.1161/01.RES.87.12.1123 CrossRefPubMed

Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107(9):1058–1070. https://doi.org/10.1161/CIRCRESAHA.110.223545 CrossRefPubMedPubMedCentral

Haendeler J, Hoffmann J, Zeiher AM, Dimmeler S (2004) Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells a novel vasculoprotective function of statins. Circulation 110(7):856–861. https://doi.org/10.1161/01.CIR.0000138743.09012.93 CrossRefPubMed

Kajstura J, Fiordaliso F, Andreoli AM, Li B, Chimenti S, Medow MS, Limana F, Nadal-Ginard B, Leri A, Anversa P (2001) IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II–mediated oxidative stress. Diabetes 50(6):1414–1424. https://doi.org/10.2337/diabetes.50.6.1414 CrossRefPubMed

Ko DT, Mamdani M, Alter DA (2004) Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 291(15):1864–1870. https://doi.org/10.1001/jama.291.15.1864 CrossRefPubMed

Li J, Sun YM, Wang LF, Li ZQ, Pan W, Cao HY (2010) Comparison of effects of simvastatin versus atorvastatin on oxidative stress in patients with coronary heart disease. Clin Cardiol 33(4):222–227. https://doi.org/10.1002/clc.20724 CrossRefPubMed

Maack C, Kartes T, Kilter H, Schäfers H-J, Nickenig G, Böhm M, Laufs U (2003) Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 108(13):1567–1574. https://doi.org/10.1161/01.CIR.0000091084.46500.BB CrossRefPubMed

Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, Tedgui A (1998) Elevated levels of 8-iso-prostaglandin F2α in pericardial fluid of patients with heart failure a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 97(16):1536–1539. https://doi.org/10.1161/01.CIR.97.16.1536 CrossRefPubMed

Moohebati M, Bidmeshgi S, Azarpazhooh MR, Daloee MH, Ghayour-Mobarhan M, Tavallaie S, Amini M, Momenzadeh A, Sahebkar A, Paydar R, Rahsepar AA, Parizadeh SMR, Akhlaghi S, Ferns GAA (2011) Simvastatin treatment reduces heat shock protein 60, 65, and 70 antibody titers in dyslipidemic patients: a randomized, double-blind, placebo-controlled, cross-over trial. Clin Biochem 44(2–3):192–197. https://doi.org/10.1016/j.clinbiochem.2010.09.016 CrossRefPubMed

Newsholme P, Haber E, Hirabara S, Rebelato E, Procopio J, Morgan D et al (2007) Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol 583(1):9–24. https://doi.org/10.1113/jphysiol.2007.135871 CrossRefPubMedPubMedCentral

Oranje WA, Sels J–PJ, Rondas-Colbers GJ, Lemmens PJ, Wolffenbuttel BH (2001) Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients. Clin Chim Acta 311(2):91–94. https://doi.org/10.1016/S0009-8981(01)00549-6 CrossRefPubMed

Pacher P, Szabó C (2006) Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Curr Opin Pharmacol 6(2):136–141. https://doi.org/10.1016/j.coph.2006.01.001 CrossRefPubMedPubMedCentral

Parizadeh SM, Azarpazhooh MR, Moohebati M, Nematy M, Ghayour-Mobarhan M, Tavallaie S et al (2011) Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. Lipids 46(4):333–340. https://doi.org/10.1007/s11745-010-3517-x CrossRefPubMed

Sahebkar, A, Kotani, K, Serban, C, Ursoniu, S, Mikhailidis, DP, Jones, SR, Ray KK, Blaha MJ, Rysz J, Toth PP, Muntner P, Lip GY, Banach M, Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group 2015a. Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials. Atherosclerosis 241(2): 433–442, DOI: https://doi.org/10.1016/j.atherosclerosis.2015.05.022

Sahebkar A, Pećin I, Tedeschi-Reiner E, Derosa G, Maffioli P, Reiner Ž (2016a) Effects of statin therapy on augmentation index as a measure of arterial stiffness: a systematic review and meta-analysis. Int J Cardiol 212:160–168. https://doi.org/10.1016/j.ijcard.2016.03.010 CrossRefPubMed

Sahebkar A, Ponziani MC, Goitre I, Bo S (2015b) Does statin therapy reduce plasma VEGF levels in humans? A systematic review and meta-analysis of randomized controlled trials. Metab Clin Exp 64(11):1466–1476. https://doi.org/10.1016/j.metabol.2015.08.002 CrossRefPubMed

Sahebkar A, Rathouska J, Derosa G, Maffioli P, Nachtigal P (2016b) Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: a systematic review and meta-analysis of controlled trials. Autoimmun Rev 15(4):344–353. https://doi.org/10.1016/j.autrev.2015.12.007 CrossRefPubMed

Sahebkar A, Rathouska J, Simental-Mendía LE, Nachtigal P (2016c) Statin therapy and plasma cortisol concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res 103:17–25. https://doi.org/10.1016/j.phrs.2015.10.013 CrossRefPubMed

Sahebkar A, Serban C, Mikhailidis DP, Undas A, Lip GYH, Muntner P, Bittner V, Ray KK, Watts GF, Hovingh GK, Rysz J, Kastelein JJP, Banach M, Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (2015c) Association between statin use and plasma d-dimer levels: a systematic review and meta-analysis of randomised controlled trials. Thromb Haemost 114(3):546–557. https://doi.org/10.1160/TH14-11-0937 PubMed

Sahebkar A, Serban C, Ursoniu S, Mikhailidis DP, Undas A, Lip GYH et al (2016d) The impact of statin therapy on plasma levels of von Willebrand factor antigen: systematic review and meta-analysis of randomised placebo-controlled trials. Thromb Haemost 115(3):520–532. https://doi.org/10.1160/TH15-08-0620 CrossRefPubMed

Satoh M, Fujimoto S, Haruna Y, Arakawa S, Horike H, Komai N, Sasaki T, Tsujioka K, Makino H, Kashihara N (2005) NAD (P) H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol-Renal Physiol 288(6):F1144–F1152. https://doi.org/10.1152/ajprenal.00221.2004 CrossRefPubMed

Save V, Patil N, Moulik N, Rajadhyaksha G (2006) Effect of atorvastatin on type 2 diabetic dyslipidemia. J Cardiovasc Pharmacol Ther 11(4):262–270. https://doi.org/10.1177/1074248406295523 CrossRefPubMed

Serban C, Sahebkar A, Ursoniu S, Mikhailidis DP, Rizzo M, Lip GYH, Kees Hovingh G, Kastelein JJP, Kalinowski L, Rysz J, Banach M (2015) A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Sci Rep 5(1). https://doi.org/10.1038/srep09902

Sezer ED, Sozmen EY, Nart D, Onat T (2011) Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation. Vasc Health Risk Manag 7:333CrossRefPubMedPubMedCentral

Shishehbor MH, Brennan M-L, Aviles RJ, Fu X, Penn MS, Sprecher DL, Hazen SL (2003) Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108(4):426–431. https://doi.org/10.1161/01.CIR.0000080895.05158.8B CrossRefPubMed

Siti HN, Kamisah Y, Kamsiah J (2015) The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). Vasc Pharmacol 71:40–56. https://doi.org/10.1016/j.vph.2015.03.005 CrossRef

Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, Kitakaze M, Liao JK (2001) Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Investig 108(10):1429–1437. https://doi.org/10.1172/JCI13350 CrossRefPubMedPubMedCentral

Tietze F (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 27(3):502–522. https://doi.org/10.1016/0003-2697(69)90064-5 CrossRefPubMed

Trachtenberg BH, Hare JM (2009) Biomarkers of oxidative stress in heart failure. Heart Fail Clin 5(4):561–577. https://doi.org/10.1016/j.hfc.2009.04.003 CrossRefPubMed

Wassmann S, Laufs U, Müller K, Konkol C, Ahlbory K, Bäumer AT et al (2002) Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22(2):300–305. https://doi.org/10.1161/hq0202.104081 CrossRefPubMed

Winterbourn CC, Hawkins RE, Brian M, Carrell R (1975) The estimation of red cell superoxide dismutase activity. J Lab Clin Med 85(2):337–341PubMed

Title: Effects of atorvastatin on myocardial oxidative and nitrosative stress in diabetic rats
Authors: Habib Yaribeygi
Nastaran Faghihi
Mohammad Taghi Mohammadi
Amirhossein Sahebkar
Publication date: 01-05-2018
Publisher: Springer London
Published in: Comparative Clinical Pathology / Issue 3/2018
Print ISSN: 1618-5641
Electronic ISSN: 1618-565X
DOI: https://doi.org/10.1007/s00580-018-2652-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Effects of atorvastatin on myocardial oxidative and nitrosative stress in diabetic rats

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2018

Management of stage III benign mammary gland tumor in a 10-year-old female dog

Effect of formaldehyde antimicrobial feed additive on the immune competence of chickens experimentally infected with a known Newcastle disease virus strain

Upregulation of two human microRNAs which might be involved in the carcinogenesis of nasopharyngeal cancer and that are promising for biomarker development

Protective potential of Tetrapleura tetraptera against trona (kaun)-induced hepatic injury in rat models

A novel herbal beverage from Moringa oleifera, Dennettia tripetala, and Citrus sinensis abates Bonny light crude oil-induced oxidative injury in rat brain and liver

Long-term effects of thyroxine-induced hyperthyroidism on the histological attributes of the oviduct in broiler breeder hens